March 2026: BPI West

Join KBI Biopharma at BPI West 2026

Booth #414

When: March 9-11, 2026

Where: San Diego Convention Center, San Diego, CA

Schedule a meeting >>

At KBI Biopharma, we deliver fully integrated drug development and biologics manufacturing services built on world-class analytics capabilities and deep technical expertise. Whether you're optimizing formulations for fill-finish, scaling to commercial manufacturing, or developing robust cell lines, visit Booth #414 to see how we accelerate your path from concept to commercialization.

Featuring the KBI Biopharma-Argonaut Manufacturing Services Partnership: Together, we deliver complete cell line to fill-finish solutions with an integrated approach that optimizes drug substance with fill-finish in mind, preventing costly challenges and accelerating timelines.

TECH TALK: Accelerating High-Concentration Biologics from Gene to GMP Through Integrated Development and Strategic Partnerships

Andrea Mislak, PhD
Sr. Director, Analytical & Formulation Sciences

Tuesday, March 10 | 3:00 PM
Manufacturing Strategy and Digitalization Track

Session Overview 

KBI's platform routinely delivers high titers for recombinant biologics, but translating these gains to high-concentration drug products often faces viscosity-driven manufacturability challenges. This presentation highlights KBI's integrated approach to high-concentration formulation development, combining early evaluation of viscosity-reducing excipients with close coordination between process development, analytics, and our strategic fill-finish partner, Argonaut Manufacturing Services. Discover how parallel development and direct transfer to fill-finish streamlines feasibility assessments and accelerates GMP readiness. 

Andrea Mislak is Senior Director of Analytical & Formulation Sciences at KBI Biopharma, where she leads teams in developing formulation strategies that bridge drug substance and drug product manufacturing. 

POSTER PRESENTATION: Establishment of a Scalable, Stable, Rapid, and Productive Cell Line Development to Process Development Pipeline Platform

Shaunak Uplekar, PhD
Director, Upstream Process Development

Poster details to be announced

Poster Overview

Previously, KBI Biopharma has demonstrated the breadth of the Selexis^® SUREtechnology Platform™ highlighting the speed, stability, and productivity of (1) transient transfection of the proprietary Selexis^® CHO-M™ cell line, (2) the Selexis^® TransposEase™ platform, and (3) the Selexis^® CHOKOL8™ afucosylated cell line. Herein, we build upon the cell line development work to demonstrate the scale up of each of these cell lines and transfection strategies at the process development scale towards early material generation. At the 200 L scale, we have successfully demonstrated that a minimum titer of 10 g/L can be achieved for an IgG mAb using Selexis^® TransposEase™ technology with both the Selexis^® CHO-M™ and Selexis^® CHOKOL8™ cell lines. These results demonstrate that Selexis^® SUREtechnology Platform™ can efficiently and seamlessly translate to process development and enable expedited timelines and robust performance for generation of cGMP materials.

View Full Conference Program Here >> 

Meet with the KBI Biopharma Team:

Schedule a meeting >>

Jen Petovic 

VP Business Development 

Chandra Kelley ​

VP Business Development

Alejandro Preciado 

Sr. Director, Business Development​

Andrea Mislak, PhD 

Sr. Director, Analytical & Formulation Sciences

Mario Morken 

Sr. Director, Business Development
 

Isabella Choi

Director, Business Development

Shaunak Uplekar, PhD  

Director, Upstream Process Development

Jesse Coe, PhD

Associate Director, Business Development, Analytical ​

Stan Sun

Product Manager, Marketing ​

---

Why Stop by the KBI Booth? 

Integrated Solutions: From cell line development through fill-finish with our Argonaut partnership, we provide seamless solutions that optimize drug substance with fill-finish in mind, preventing costly late-stage challenges and accelerating timelines.​ One partnership. Seamless solutions.

Scientific Excellence: World-class analytical and formulation capabilities that reduce risk and provide the confidence you need for regulatory submissions and commercial success.

Manufacturing Expertise: Robust process development and cGMP manufacturing services for both mammalian and microbial platforms, from early development through commercial scale.

Partnership with Argonaut Manufacturing Services: Complete cell line to fill-finish solutions with simplified processes, accelerated timelines, and streamlined quality processes.

Ready to see how we accelerate biologics programs like yours? Stop by Booth #414 or schedule a one-on-one meeting with our team.

 

---

About KBI Biopharma: 

KBI Biopharma is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of our 1400+ client partners, we work closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, we deliver robust process development and clinical and commercial cGMP manufacturing services for mammalian and microbial programs. Recognized for quality manufacturing, we help clients advance drug candidates into the clinic and beyond. 

Learn more about KBI Biopharma >>

ABOUT THE EVENT: